Kamel Ehab M, Jichlinski Patrice, Prior John O, Meuwly Jean-Yves, Delaloye Jean-Francois, Vaucher Laurent, Malterre Jerome, Castaldo Sandra, Leisinger Hans-Juerg, Delaloye Angelika Bischof
Department of Nuclear Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
J Nucl Med. 2006 Nov;47(11):1803-7.
Our aim was to evaluate the role of forced diuresis in improving the diagnostic accuracy of abdominopelvic (18)F-FDG PET.
Thirty-two patients were enrolled. Besides the presence of known intravesical tumors or undefined renal lesions on the initial PET scan, the inclusion criterion was the appearance of indeterminate or equivocal (18)F-FDG foci that extended along the course of the urinary tract and could not confidently be separated from urinary activity. For each patient, a second abdominopelvic PET study was performed after intravenous injection of 0.5 mg of furosemide per kilogram of body weight (maximum, 40 mg) coupled with parenteral infusion of physiologic saline.
Forced diuresis coupled with parenteral hydration eliminated any significant (18)F-FDG activity from the lower urinary tract in 31 (97%) of 32 patients after the bladder had been voided 3 successive times. Twelve intravesical lesions were visualized with outstanding clarity, whereas radiologic suspicion of locally recurrent bladder tumors was ruled out in 3 patients. Among 14 indeterminate or equivocal extravesical foci, 7 were deemed of no clinical value because they disappeared after furosemide challenge, whereas 7 persisting foci were proven to be true-positive PET findings. The performance of (18)F-FDG PET in characterizing 3 renal-space-occupying lesions could not be improved by our protocol.
Furosemide challenge has the potential to noninvasively resolve the inherent (18)F-FDG contrast handicap in the lower urinary tract.
我们的目的是评估强制利尿在提高腹盆腔(18)F-FDG PET诊断准确性方面的作用。
纳入32例患者。除了初始PET扫描时存在已知的膀胱内肿瘤或未明确的肾脏病变外,纳入标准是出现沿尿路走行的不确定或可疑的(18)F-FDG病灶,且无法可靠地与尿液活性区分开。对于每位患者,在静脉注射每千克体重0.5毫克呋塞米(最大剂量40毫克)并同时静脉输注生理盐水后,进行第二次腹盆腔PET检查。
在膀胱连续排空3次后,32例患者中有31例(97%)通过强制利尿联合静脉补液消除了下尿路中任何显著的(18)F-FDG活性。12个膀胱内病变清晰可见,而3例患者排除了局部复发性膀胱肿瘤的影像学怀疑。在14个不确定或可疑的膀胱外病灶中,7个因呋塞米激发试验后消失而被认为无临床价值,而7个持续存在的病灶被证实为PET真阳性结果。我们的方案未能改善(18)F-FDG PET对3个肾脏占位性病变的特征性表现。
呋塞米激发试验有可能无创地解决下尿路中固有的(18)F-FDG对比障碍。